Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure

Stephen R. Durham, H. S. Nelson, H. Nolte, D. I. Bernstein, Peter Socrates Creticos, Z. Li, J. S. Andersen

Research output: Contribution to journalArticle

Abstract

Background: The objective was to evaluate the association between grass pollen exposure, allergy symptoms and impact on measured treatment effect after grass sublingual immunotherapy (SLIT)-tablet treatment. Methods: The association between grass pollen counts and total combined rhinoconjunctivitis symptom and medication score (TCS) was based on a post hoc analysis of data collected over six trials and seven grass pollen seasons across North America and Europe, including 2363 subjects treated with grass SLIT-tablet or placebo. Daily pollen counts were obtained from centralized pollen databases. The effect of treatment on the relationship between the TCS and pollen counts was investigated, and the relative difference between grass SLIT-tablet and placebo as a function of average grass pollen counts was modelled by linear regression. Results The magnitude of treatment effect based on TCS was greater with higher pollen exposure (P <0.001). The relative treatment effect in terms of TCS for each trial was correlated with the average grass pollen exposure during the first period of the season, with predicted reduction in TCS = 12% + 0.35% × pollen count (slope significantly different from 0, P = 0.003; R2 = 0.66). Corresponding correlations to the entire grass pollen season and to the peak season were equally good, whereas there was a poor correlation between difference in measured efficacy and pollen exposure during the last part of the season. Conclusions: In seasonal allergy trials with grass SLIT-tablet, the observed treatment effect is highly dependent on pollen exposure with the magnitude being greater with higher pollen exposure. This is an important relationship to consider when interpreting individual clinical trial results.

Original languageEnglish (US)
Pages (from-to)617-623
Number of pages7
JournalAllergy: European Journal of Allergy and Clinical Immunology
Volume69
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Pollen
Poaceae
Immunotherapy
Hypersensitivity
Sublingual Immunotherapy
Tablets
Therapeutics
Placebos
Seasonal Allergic Rhinitis
North America
Linear Models
Clinical Trials
Databases

Keywords

  • allergen-specific immunotherapy
  • grass pollen counts
  • grass sublingual immunotherapy tablet

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. / Durham, Stephen R.; Nelson, H. S.; Nolte, H.; Bernstein, D. I.; Creticos, Peter Socrates; Li, Z.; Andersen, J. S.

In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 69, No. 5, 2014, p. 617-623.

Research output: Contribution to journalArticle

Durham, Stephen R. ; Nelson, H. S. ; Nolte, H. ; Bernstein, D. I. ; Creticos, Peter Socrates ; Li, Z. ; Andersen, J. S. / Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure. In: Allergy: European Journal of Allergy and Clinical Immunology. 2014 ; Vol. 69, No. 5. pp. 617-623.
@article{248c5195472c4dbaa90ab5050dab0a0e,
title = "Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure",
abstract = "Background: The objective was to evaluate the association between grass pollen exposure, allergy symptoms and impact on measured treatment effect after grass sublingual immunotherapy (SLIT)-tablet treatment. Methods: The association between grass pollen counts and total combined rhinoconjunctivitis symptom and medication score (TCS) was based on a post hoc analysis of data collected over six trials and seven grass pollen seasons across North America and Europe, including 2363 subjects treated with grass SLIT-tablet or placebo. Daily pollen counts were obtained from centralized pollen databases. The effect of treatment on the relationship between the TCS and pollen counts was investigated, and the relative difference between grass SLIT-tablet and placebo as a function of average grass pollen counts was modelled by linear regression. Results The magnitude of treatment effect based on TCS was greater with higher pollen exposure (P <0.001). The relative treatment effect in terms of TCS for each trial was correlated with the average grass pollen exposure during the first period of the season, with predicted reduction in TCS = 12{\%} + 0.35{\%} × pollen count (slope significantly different from 0, P = 0.003; R2 = 0.66). Corresponding correlations to the entire grass pollen season and to the peak season were equally good, whereas there was a poor correlation between difference in measured efficacy and pollen exposure during the last part of the season. Conclusions: In seasonal allergy trials with grass SLIT-tablet, the observed treatment effect is highly dependent on pollen exposure with the magnitude being greater with higher pollen exposure. This is an important relationship to consider when interpreting individual clinical trial results.",
keywords = "allergen-specific immunotherapy, grass pollen counts, grass sublingual immunotherapy tablet",
author = "Durham, {Stephen R.} and Nelson, {H. S.} and H. Nolte and Bernstein, {D. I.} and Creticos, {Peter Socrates} and Z. Li and Andersen, {J. S.}",
year = "2014",
doi = "10.1111/all.12373",
language = "English (US)",
volume = "69",
pages = "617--623",
journal = "Allergy: European Journal of Allergy and Clinical Immunology",
issn = "0105-4538",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Magnitude of efficacy measurements in grass allergy immunotherapy trials is highly dependent on pollen exposure

AU - Durham, Stephen R.

AU - Nelson, H. S.

AU - Nolte, H.

AU - Bernstein, D. I.

AU - Creticos, Peter Socrates

AU - Li, Z.

AU - Andersen, J. S.

PY - 2014

Y1 - 2014

N2 - Background: The objective was to evaluate the association between grass pollen exposure, allergy symptoms and impact on measured treatment effect after grass sublingual immunotherapy (SLIT)-tablet treatment. Methods: The association between grass pollen counts and total combined rhinoconjunctivitis symptom and medication score (TCS) was based on a post hoc analysis of data collected over six trials and seven grass pollen seasons across North America and Europe, including 2363 subjects treated with grass SLIT-tablet or placebo. Daily pollen counts were obtained from centralized pollen databases. The effect of treatment on the relationship between the TCS and pollen counts was investigated, and the relative difference between grass SLIT-tablet and placebo as a function of average grass pollen counts was modelled by linear regression. Results The magnitude of treatment effect based on TCS was greater with higher pollen exposure (P <0.001). The relative treatment effect in terms of TCS for each trial was correlated with the average grass pollen exposure during the first period of the season, with predicted reduction in TCS = 12% + 0.35% × pollen count (slope significantly different from 0, P = 0.003; R2 = 0.66). Corresponding correlations to the entire grass pollen season and to the peak season were equally good, whereas there was a poor correlation between difference in measured efficacy and pollen exposure during the last part of the season. Conclusions: In seasonal allergy trials with grass SLIT-tablet, the observed treatment effect is highly dependent on pollen exposure with the magnitude being greater with higher pollen exposure. This is an important relationship to consider when interpreting individual clinical trial results.

AB - Background: The objective was to evaluate the association between grass pollen exposure, allergy symptoms and impact on measured treatment effect after grass sublingual immunotherapy (SLIT)-tablet treatment. Methods: The association between grass pollen counts and total combined rhinoconjunctivitis symptom and medication score (TCS) was based on a post hoc analysis of data collected over six trials and seven grass pollen seasons across North America and Europe, including 2363 subjects treated with grass SLIT-tablet or placebo. Daily pollen counts were obtained from centralized pollen databases. The effect of treatment on the relationship between the TCS and pollen counts was investigated, and the relative difference between grass SLIT-tablet and placebo as a function of average grass pollen counts was modelled by linear regression. Results The magnitude of treatment effect based on TCS was greater with higher pollen exposure (P <0.001). The relative treatment effect in terms of TCS for each trial was correlated with the average grass pollen exposure during the first period of the season, with predicted reduction in TCS = 12% + 0.35% × pollen count (slope significantly different from 0, P = 0.003; R2 = 0.66). Corresponding correlations to the entire grass pollen season and to the peak season were equally good, whereas there was a poor correlation between difference in measured efficacy and pollen exposure during the last part of the season. Conclusions: In seasonal allergy trials with grass SLIT-tablet, the observed treatment effect is highly dependent on pollen exposure with the magnitude being greater with higher pollen exposure. This is an important relationship to consider when interpreting individual clinical trial results.

KW - allergen-specific immunotherapy

KW - grass pollen counts

KW - grass sublingual immunotherapy tablet

UR - http://www.scopus.com/inward/record.url?scp=84898471626&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84898471626&partnerID=8YFLogxK

U2 - 10.1111/all.12373

DO - 10.1111/all.12373

M3 - Article

C2 - 24605984

AN - SCOPUS:84898471626

VL - 69

SP - 617

EP - 623

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

SN - 0105-4538

IS - 5

ER -